Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy
In the past, adoptive immunotherapy often failed because the transferred immune cells were inactive in vivo. This disclosure provides a method of producing immune cells that are highly active in vivo. The immune cells may be expanded in vitro in the presence of an adenosine receptor agonist or an antisense nucleic acid that downregulates expression of an adenosine receptor, for example. The immune cells may be tumor-infiltrating lymphocytes (TIL), cytotoxic T lymphocytes (CTL), natural killer (NK) cells, or lymphokine-activated killer (LAK) cells, for example. The methods described herein may be used to treat a number of diseases including cancer, infectious diseases, and immunodeficiencies.
1. A method of making a lymphocyte preparation, comprising:
(a) collecting an enriched population of tumor-reactive lymphocytes and/or a natural killer cell population from a subject;
(b) culturing and/or expanding the enriched population of tumor-reactive lymphocytes and/or the natural killer cell population in vitro in the absence of an adenosine receptor agonist; and
(c) culturing and/or expanding the enriched population of tumor-reactive lymphocytes and/or the natural killer cell population from (b) in vitro in the presence of an agonist of an adenosine receptor,
thereby making a lymphocyte preparation wherein the lymphocyte preparation has anti-tumor activity.
2. The method of claim 1 , wherein step (a), (b) or (c) further comprises genetically modifying the enriched population of tumor-reactive lymphocytes and/or a natural killer cell population with a recombinant T cell receptor.
3. The method of claim 1 , further comprising enriching the tumor-reactive lymphocytes and/or the natural killer cell population of step (c) for cells resistant to adenosine.
4. The method of claim 1 , further comprising removing from the enriched population of tumor-reactive lymphocytes and/or the natural killer cell population of step (c) cells sensitive to inhibition by adenosine.
5. The method of claim 1 , further comprising transfecting the enriched population of tumor-reactive lymphocytes and/or the natural killer cell population with a recombinant T cell receptor specific to an antigen.
6. The method of claim 1 , further comprising a step of adding an immune cell stimulating ligand to the enriched population of tumor-reactive lymphocytes and/or the natural killer cell population.
7. The method of claim 6 , wherein the immune cell stimulating ligand is an anti-CD3 and/or anti-CD28 antibody.
8. The method of claim 1 , wherein the subject is human.
9. The method of claim 1 , wherein the lymphocyte preparation comprises tumor infiltrating lymphocytes, tumor-reactive lymphocytes, natural killer cells, or lymphokine-activated killer cells.
10. The method of claim 1 , further comprising formulating a medicament comprising the lymphocyte preparation.
11. The method of claim 1 , wherein the enriched population of tumor-reactive lymphocytes and/or a natural killer cell population is cultured or expanded for about five days in the absence of an adenosine receptor agonist, and then for about two days in the presence of an adenosine receptor agonist.
12. The method of claim 1 , wherein the lymphocyte preparation is capable of inhibiting a tumor in vivo.
13. The method of claim 1 , wherein the lymphocyte preparation is resistant to inhibition in inflamed or diseased tissues in vivo.
14. A method of making a lymphocyte preparation, comprising:
(a) collecting a cytotoxic T lymphocyte population from a subject;
(b) culturing and/or expanding the cytotoxic T lymphocyte population in vitro in the absence of an adenosine receptor agonist;
(c) culturing and/or expanding the cytotoxic T lymphocyte population from (b) in vitro in the presence of an agonist of an adenosine receptor, and
(d) genetically modifying the cells of either (a), (b) or (c) with a recombinant T cell receptor specific to a tumor antigen,
thereby making a lymphocyte preparation wherein the lymphocyte preparation has anti-tumor activity.
15. The method of claim 14 , further comprising enriching the cytotoxic T lymphocyte population of step (c) for cells resistant to adenosine.
16. The method of claim 14 , further comprising removing from the cytotoxic T lymphocyte population of step (c) cells sensitive to inhibition by adenosine.
17. The method of claim 14 , wherein step (d) comprises transfecting the cytotoxic T lymphocyte population with a recombinant T cell receptor specific to an antigen.
18. The method of claim 14 , further comprising a step of adding an immune cell stimulating ligand to the cytotoxic T lymphocyte population.
19. The method of claim 18 , wherein the immune cell stimulating ligand is an anti-CD3 and/or anti-CD28 antibody.
20. The method of claim 14 , wherein the subject is human.
21. The method of claim 14 , wherein the lymphocyte preparation comprises cytotoxic T lymphocytes or lymphokine-activated killer cells.
22. The method of claim 14 , further comprising formulating a medicament comprising the lymphocyte preparation.
23. The method of claim 14 , wherein cytotoxic T lymphocyte population is cultured or expanded for about five days in the absence of an adenosine receptor agonist, and then for about two days in the presence of an adenosine receptor agonist.
24. The method of claim 14 , wherein the lymphocyte preparation is capable of inhibiting a tumor in vivo.
25. The method of claim 14 , wherein the lymphocyte preparation is resistant to inhibition in inflamed or diseased tissues in vivo.
26. A method of making a lymphocyte preparation, comprising:
(a) collecting a cytotoxic T lymphocyte population from a subject;
(b) culturing and/or expanding said cytotoxic T lymphocyte population in vitro in the absence of an adenosine receptor agonist and under conditions selective for cytotoxic T lymphocytes that recognize tumor cells; and
(c) culturing and/or expanding the tumor cell specific cytotoxic T lymphocyte population from (b) in vitro in the presence of an agonist of an adenosine receptor,
thereby making a lymphocyte preparation wherein the lymphocyte preparation has anti-tumor activity.
27. The method of claim 26 , further comprising enriching the cytotoxic T lymphocyte population of step (c) for cells resistant to adenosine.
28. The method of claim 26 , further comprising removing from the cytotoxic T lymphocyte population cells of step (c) sensitive to inhibition by adenosine.
29. The method of claim 26 , further comprising genetically modifying the cytotoxic T lymphocyte population with a recombinant T cell receptor specific to an antigen.
30. The method of claim 26 , further comprising tranfecting the cytotoxic T lymphocyte population with a recombinant T cell receptor specific to an antigen.
31. The method of claim 26 , further comprising a step of adding an immune cell stimulating ligand to the cytotoxic T lymphocyte population.
32. The method of claim 31 , wherein the immune cell stimulating ligand is an anti-CD3 and/or anti-CD28 antibody.
33. The method of claim 26 , wherein the subject is human.
34. The method of claim 26 , wherein the lymphocyte preparation comprises cytotoxic T lymphocytes or lymphokine-activated killer cells.
35. The method of claim 26 , further comprising formulating a medicament comprising the lymphocyte preparation.
36. The method of claim 26 , wherein cytotoxic T lymphocyte population is cultured or expanded for about five days in the absence of an adenosine receptor agonist, and then for about two days in the presence of an adenosine receptor agonist.
37. The method of claim 26 , wherein the lymphocyte preparation is capable of inhibiting a tumor in vivo.
38. The method of claim 26 , wherein the lymphocyte preparation is resistant to inhibition in inflamed or diseased tissues in vivo.